ABSTRACT
The aim of this study was to examine the daily practice patterns of Symbicort® Maintenance and Reliever Therapy (SMART) in Korean asthmatic patients and to analyze clinical signs related to overuse. This study used an observational, multicenter, noninterventional, prospective, uncontrolled design for examining asthmatic patients prescribed SMART to assess the frequency and pattern of Symbicort® usage as a maintenance and reliever medication. The characteristics of patients showing signs of overuse (frequency of inhalation: 8 or more times per day) were also analyzed. Among the 1,518 patients analyzed, 1,292 (85.1%) completed the trial. The number of mean inhalations per day was 2.14±1.15; the number of patients who had at least 1 as needed usage (PRN) inhalation per day was 843 (55.5%); the mean frequency of PRN use was 0.25±0.67 inhalations per day. The number of patients who overused for at least 1 day was 260 (17.1%). In particular, young patients, patients with limited physical activity, and patients with nocturnal symptoms demonstrated high frequency of overuse. The frequency of overuse during SMART was not high in Korean asthmatic patients and the asthma status of follow-up outpatients improved overall. However, there is a need for careful education targeted toward younger patients, patients with limited physical activity, and patients with nocturnal symptoms owing to their tendency to frequently overuse.
Subject(s)
Humans , Asthma , Budesonide , Education , Follow-Up Studies , Formoterol Fumarate , Inhalation , Korea , Motor Activity , Outpatients , Prescription Drug Overuse , Prospective StudiesABSTRACT
Objective To investigate the effect of Montelukast Combined with Symbicort in severe asthma treatment and intervention. Methods The treatment according to different interventions will be January 2015 to January 2017 in our hospital 80 cases of severe asthma groups:control group with routine nursing intervention for a letter form treatment, the observation group with high quality nursing the intervention of montelukast Symbicort treatment; detailed records of patients in the two groups of experimental data, and the data for comparative analysis, to explore the combination of montelukast and Symbicort in severe asthma treatment and intervention effect. Results The high quality nursing intervention meng montelukast Symbicort (observation group) for the treatment of severe clinical the effect of nursing intervention in patients with asthma is better than conventional Symbicort (control group) clinical efficacy, clinical symptoms improved better than the control group, nursing satisfaction was higher than the control group, the difference was statistically significant (P< 0.05). Conclusion The high quality nursing intervention of patients with severe asthma montelukast Symbicort treatment effect significantly, can effectively improve the clinical symptoms of patients, nursing satisfaction is high, it is widely used in clinical treatment of patients with severe asthma intervention.
ABSTRACT
Objective To evaluate the level of clinical treatment in severe stable double COPD noninvasive positive pressure ventilation (BiPAP) + tiotropium + Symbicort regimen effect. Methods 210 patients with moderate to severe COPD patients as the research object, divided into group I, group II, group III, 1 BiPAP + group with tiotropium bromide in the treatment scheme, group II Implementation of tiotropium + Symbicort treatment group enabled BiPAP + tiotropium + Symbicort. Results Group comparison indexes of pulmonary function level and lung function indexes were found in the three groups after treatment showed a rising trend comparison between groups after treatment, the levels of the indicators of lung function showed the most significant increases in group I, group II indexes of pulmonary function approximation. In group 6-MWD group with the longest distance difference index (P<0.05), group II and group I but the difference between does not have statistical significance Conclusion BiPAP + tiotropium bromide + Cr is an effective treatment for moderate and severe stable COPD, which is beneficial to improve the quality of life of patients.
ABSTRACT
Objective To investigate the analysis of Symbicort in stable stage of chronic obstructive pulmonary disease treatment and intervention. Methods 80 patients with chronic obstructive pulmonary disease in stable period from June 2014-2016 year in May in our hospital were randomly divided into control group and experimental group, 40 cases in each group. The control group of patients with the use of simple Symbicort treatment and routine nursing care to patients, patients in the experimental group using Symbicort combined with Bailing Capsule for treatment, and the implementation of targeted nursing intervention measures, compare the effect of two groups of patients and nursing satisfaction. Results the clinical treatment of patients in the experimental group the total efficiency 95.0%, nursing satisfaction was 97.5%, the control of clinical patients in the treatment group the total effective rate was 80.0%, nursing satisfaction was 87.5%, the experimental group was significantly higher than the control group, the difference was statistically significant (P<0.05). Conclusion Chronic In the stable period of obstructive pulmonary disease, the combination of Xin Yi capsule combined with Bailing capsule can effectively improve the pulmonary function of patients and improve the clinical therapeutic effect, and is worthy of popularization and application in clinic.
ABSTRACT
Objective To explore the influence pulmonary function and inflammatory factors of symbicort combined with ambroxol hydrochloride in the treatment of acute exacerbation of chronic obstructive pulmonary disease( AECOPD) .Methods 86 patients with AECOPD were divided into control group 43 cases and treatment group 43 cases according to the computer random number table method.The control group was given intravenous injection of ambroxol hydrochloride 60 mg/time, 2 times/day, and the treatment group was given inhalation of symbicort 2 inhaling/times, 3 times/day on the basis of the control group.After 7 day treatment, the clinical efficacy and adverse reactions of two groups were observed.The percentage of forced vital capacity ( FVC%) , percentage of forced expiratory volume of 1 seconds( FEV1 %) , percentage of mid expiratory flow predicted value( MMF%) , percentage of max volume predicted value(MVV%) were measured by pulmonary function test apparatus, and the value of FEV1%/FVC% was calculated.The levels of serum tumor necrosis factor alpha(TNF-α), c-reactive protein(CRP) and interleukin 6(IL-6) were detected by ELISA.Results The total effective rate of treatment group and control group were 93.02%(40/43) and 74.42%(32/43), the difference was statistically significant(P <0.05).After treatment the FVC%(2.58 ±0.25),FEV1%(1.87 ±0.15),MMF%(70.24 ±5.86)and MVV%(72.43 ±4.35) in treatment group were higher than the control group (2.21 ±0.27),(1.68 ±0.16),(63.14 ±5.68)and 65.12 ±4.16), the difference was statistically significant(P<0.05).The levels of serum TNF-α(13.87 ±4.12)μg/mL,CRP(9.14 ±3.76)mg/mLand IL-6(76.07 ±10.14)pg/mL in treatment group were lower than the control group (16.56 ±6.48)μg/mL,(12.46 ±3.89)mg/mL and(89.55 ±11.24)pg/mL,the difference was statistically significant(P<0.05).The adverse reactions were mainly for heartburn, nausea, vomiting and skin rashes in the control group,and the adverse reactions were mainly for heart palpitations, headache, nausea, rashes, vomiting in the treatment group, the incidences of adverse reactions 23.26%(10/43) in treatment group compared to control group 18.60%(8/43) was no statistically significant difference.Conclusion The symbicort combined with ambroxol hydrochloride in the treatment of AECOPD have clinical curative effect, can improve the patient's lung function, reduce inflammation, have less adverse reactions.It was worthy of clinical popularization and application.
ABSTRACT
Objective To investigate the desensitization therapy combined with budesonide/symbicort inhalant for treatment of allergic bronchial asthma.Methods 80 patients with allergic asthma randomly divided into observation group and control group,each group of 40 cases.Two groups were given conventional treatment and desensitization therapy,the control group required glucocorticoid,the observation group received budesonide/symbicort inhalant.were evaluated.Results The total effective rate in the observation group was 92.5％ (37/40),the control group was 72.5％(29/40),the difference was statistically significant (P ＜0.05).FEV1.0％ in the two groups after treatment,PET and symptom score were significantly improved after treatment(P ＜0.05).The observation group improved more significantly than that of the control group (P ＜0.05).The incidence of adverse reaction in observation group was 15％(6/40),significantly less than that in the control group 35％ (14/40),the difference was statistically significant (P ＜0.05).Conclusion Desensitization therapy combined with budesonide/symbicort inhalant in asthma symptoms could improve asthma and lung function,which has high safety and worthy of clinical application.
ABSTRACT
Retrospective DUE is the reviewing of drug therapy after the patient has received the medication. Asthma is a common chronic disease in Malaysia. A National Health and Morbidity Survey in 1996 indicated that asthma prevalence in Malaysia was 4.2%. Statistics on the causes of death have noted asthma as one of the 10 principal causes of death (7.3%) in Malaysia. The purpose of the study was to compare drug utilization patterns amongst the asthmat-ics from the past two years (since 2009) in Kedah state. Asthmatics admitted to the hospital in the preceding two years were analyzed by their patient charts. This study focused on both smoker and non smoker asthmatics. It was observed that salbutamol was most commonly prescribed, followed by montelukast and prednisolone. In the combination therapy, the most commonly prescribed was Symbicort, followed by seretide and combivent. Corticoste-roids constituted the most prevalent class, followed by beta-2 agonists, leukotriene modifiers and methylxanthines. The study presented the most recent scenario on drug utilization pattern of asthmatics in Kedah state.
ABSTRACT
Retrospective DUE is the reviewing of drug therapy after the patient has received the medication. Asthma is a common chronic disease in Malaysia. A National Health and Morbidity Survey in 1996 indicated that asthma prevalence in Malaysia was 4.2%. Statistics on the causes of death have noted asthma as one of the 10 principal causes of death (7.3%) in Malaysia. The purpose of the study was to compare drug utilization patterns amongst the asthmat-ics from the past two years (since 2009) in Kedah state. Asthmatics admitted to the hospital in the preceding two years were analyzed by their patient charts. This study focused on both smoker and non smoker asthmatics. It was observed that salbutamol was most commonly prescribed, followed by montelukast and prednisolone. In the combination therapy, the most commonly prescribed was Symbicort, followed by seretide and combivent. Corticoste-roids constituted the most prevalent class, followed by beta-2 agonists, leukotriene modifiers and methylxanthines. The study presented the most recent scenario on drug utilization pattern of asthmatics in Kedah state.
ABSTRACT
Objective To observe the clinical effect of modified Zhisou powder and Symbicort Turbuhaler simultaneously on patients with Cough Variant Asthma. Methods 120 patients with Cough Variant Asthma were randomly recurited into two groups. 60 patients in the treatment group were treated with modified Zhisou powder and Symbicort Turbuhaler; 60 patients in the control group were treated with Symbicort Turbuhaler. 4 weeks was a therapeutic course in both group. Results The markedly controlled rate (MCR) (clinical control+excenence)of the treatment group was 83.3%, obviously surpassed the control group (70.0%) (P＜0.05); There was obvious improvement of cough, expectoration, breath lessness and throaty pruritus after the therapy in both groups, but it was much better in the treatment group than the control group(P＜0.05). The pulmonary function was significantly improved after treatment in both groups(FEV1, FEV1% and PEF, P＜0.05). The improvement showed significant difference between the two groups(P＜0.05). There was obvious decrease of EOS, IL-5 and ECP in both groups. The decrease of ECP and IL-5 in the treatment group was greater than the control group(P＜0.01). Conclusion The therapy of modified Zhisou powder and Symbicort Turbuhaler has advantage over pure western therapy.